JP2025094100A5 - - Google Patents
Info
- Publication number
- JP2025094100A5 JP2025094100A5 JP2025044149A JP2025044149A JP2025094100A5 JP 2025094100 A5 JP2025094100 A5 JP 2025094100A5 JP 2025044149 A JP2025044149 A JP 2025044149A JP 2025044149 A JP2025044149 A JP 2025044149A JP 2025094100 A5 JP2025094100 A5 JP 2025094100A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- represents tert
- butyloxycarbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762536271P | 2017-07-24 | 2017-07-24 | |
| US62/536,271 | 2017-07-24 | ||
| US201762573894P | 2017-10-18 | 2017-10-18 | |
| US62/573,894 | 2017-10-18 | ||
| PCT/US2018/043338 WO2019023147A1 (en) | 2017-07-24 | 2018-07-23 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY |
| JP2020503754A JP7412328B2 (ja) | 2017-07-24 | 2018-07-23 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| JP2023218835A JP7654767B2 (ja) | 2017-07-24 | 2023-12-26 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023218835A Division JP7654767B2 (ja) | 2017-07-24 | 2023-12-26 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025094100A JP2025094100A (ja) | 2025-06-24 |
| JP2025094100A5 true JP2025094100A5 (https=) | 2025-10-21 |
| JP7813931B2 JP7813931B2 (ja) | 2026-02-13 |
Family
ID=63143410
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503754A Active JP7412328B2 (ja) | 2017-07-24 | 2018-07-23 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| JP2023218835A Active JP7654767B2 (ja) | 2017-07-24 | 2023-12-26 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| JP2025044149A Active JP7813931B2 (ja) | 2017-07-24 | 2025-03-18 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503754A Active JP7412328B2 (ja) | 2017-07-24 | 2018-07-23 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| JP2023218835A Active JP7654767B2 (ja) | 2017-07-24 | 2023-12-26 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US11203579B2 (https=) |
| EP (2) | EP3658539B1 (https=) |
| JP (3) | JP7412328B2 (https=) |
| KR (1) | KR102565167B1 (https=) |
| CN (3) | CN117209447A (https=) |
| AU (1) | AU2018307743C1 (https=) |
| BR (1) | BR112020001476A2 (https=) |
| CA (1) | CA3068836A1 (https=) |
| CL (1) | CL2020000215A1 (https=) |
| CO (1) | CO2020000527A2 (https=) |
| CR (1) | CR20200037A (https=) |
| CU (1) | CU24615B1 (https=) |
| DK (1) | DK3658539T3 (https=) |
| DO (1) | DOP2020000012A (https=) |
| EC (1) | ECSP20005581A (https=) |
| ES (1) | ES2988798T3 (https=) |
| FI (1) | FI3658539T3 (https=) |
| HR (1) | HRP20240521T1 (https=) |
| HU (1) | HUE066566T2 (https=) |
| IL (1) | IL271259B2 (https=) |
| JO (1) | JOP20200011B1 (https=) |
| LT (1) | LT3658539T (https=) |
| MX (1) | MX2020000911A (https=) |
| NZ (1) | NZ761026A (https=) |
| PE (1) | PE20200723A1 (https=) |
| PH (1) | PH12020500127A1 (https=) |
| PL (1) | PL3658539T3 (https=) |
| PT (1) | PT3658539T (https=) |
| RS (1) | RS65492B1 (https=) |
| SA (1) | SA520411125B1 (https=) |
| SG (1) | SG11201912166XA (https=) |
| SI (1) | SI3658539T1 (https=) |
| WO (1) | WO2019023147A1 (https=) |
| ZA (1) | ZA201908154B (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3634951B8 (en) * | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| RS65492B1 (sr) | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| KR102717072B1 (ko) | 2017-10-18 | 2024-10-15 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| KR20200087759A (ko) | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| CN112654350A (zh) * | 2018-07-03 | 2021-04-13 | 诺华股份有限公司 | 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法 |
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| US12187702B2 (en) | 2018-08-15 | 2025-01-07 | Inflazome Limited | Sulfonamideurea compounds |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| EP3880666B1 (en) | 2018-11-13 | 2023-06-28 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| CR20210235A (es) * | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| CN113015730A (zh) | 2018-11-13 | 2021-06-22 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| CN113286784A (zh) * | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| CN120208846A (zh) | 2019-01-14 | 2025-06-27 | 载度思生命科学有限公司 | 经取代的磺酰脲类衍生物 |
| EP3914585A1 (en) * | 2019-01-23 | 2021-12-01 | Novartis AG | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity |
| GB201905265D0 (en) | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
| GB201908219D0 (en) | 2019-06-10 | 2019-07-24 | Axalbion Sa | Therapeutic use of a compound |
| CN114641466B (zh) | 2019-06-12 | 2025-09-30 | 诺瑟拉有限公司 | 磺酰脲衍生物及其用途 |
| US20220378801A1 (en) | 2019-06-21 | 2022-12-01 | Ac Immune Sa | Novel compounds |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| CN110590576A (zh) * | 2019-08-15 | 2019-12-20 | 安徽金禾实业股份有限公司 | 一种4-多氟代甲氧基邻苯二胺的制备方法 |
| EP4013761A1 (en) | 2019-08-16 | 2022-06-22 | Inflazome Limited | Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors |
| CN114555609A (zh) | 2019-08-16 | 2022-05-27 | 英夫拉索姆有限公司 | 用作nlrp3抑制剂的大环磺酰胺衍生物 |
| JP2022547882A (ja) | 2019-09-06 | 2022-11-16 | インフレイゾーム リミテッド | Ｎｌｒｐ３阻害剤 |
| CN117105890A (zh) * | 2019-11-12 | 2023-11-24 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| KR102333562B1 (ko) * | 2019-12-03 | 2021-12-01 | 전남대학교 산학협력단 | Nlrp3 인플라마좀 억제제를 포함하는 노인성 치주질환 예방, 개선 또는 치료용 조성물 및 그의 방법 |
| EP4093509A1 (en) * | 2020-01-22 | 2022-11-30 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as nlrp3 modulators |
| JP2023513935A (ja) | 2020-02-18 | 2023-04-04 | インフレイゾーム リミテッド | 化合物 |
| US12428391B2 (en) | 2020-06-11 | 2025-09-30 | Cisen Pharmaceutical Co., Ltd | Dimethylsulfoximine derivative |
| MX2022014709A (es) | 2020-06-19 | 2022-12-16 | Ac Immune Sa | Derivados de dihidrooxazol y tiourea que modulan la ruta del inflamasoma de la proteina 3 que contiene el dominio pirina de la familia del receptor similar al dominio de oligomerizacion de union a nucleotido (nlrp3). |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| CN116783184A (zh) | 2020-09-04 | 2023-09-19 | 诺瑟拉有限公司 | 含有烷基-氧杂环烷基部分的氨磺酰基脲衍生物及其用途 |
| KR102409344B1 (ko) * | 2020-09-22 | 2022-06-15 | 가톨릭대학교 산학협력단 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
| KR102409345B1 (ko) * | 2020-09-22 | 2022-06-16 | 가톨릭대학교 산학협력단 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
| WO2022105852A1 (zh) | 2020-11-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| CN116507608A (zh) * | 2020-11-20 | 2023-07-28 | 戴纳立制药公司 | 化合物、组合物和方法 |
| CN113061111A (zh) * | 2021-03-16 | 2021-07-02 | 无锡海伦生物科技有限公司 | 具有光交联活性的氨基酸类化合物的制备方法 |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CN116635374B (zh) * | 2021-05-10 | 2025-05-06 | 康百达（四川）生物医药科技有限公司 | 酰胺衍生物及其应用 |
| TWI815439B (zh) * | 2021-05-10 | 2023-09-11 | 大陸商成都百裕製藥股份有限公司 | 醯胺衍生物及其應用 |
| WO2022237782A1 (zh) * | 2021-05-10 | 2022-11-17 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| CN115616216B (zh) * | 2021-07-15 | 2025-08-12 | 华南理工大学 | 抑制或阻断faah与nlrp3之间相互作用的制剂的用途 |
| IL309085A (en) | 2021-07-23 | 2024-02-01 | Novartis Ag | Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis |
| CN118302415A (zh) * | 2021-12-03 | 2024-07-05 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物的制备方法 |
| CN118355000A (zh) * | 2021-12-03 | 2024-07-16 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物的盐型及晶型 |
| CN118541366A (zh) | 2021-12-22 | 2024-08-23 | Ac免疫有限公司 | 二氢噁唑衍生物化合物 |
| CN114436851B (zh) * | 2022-01-17 | 2023-08-22 | 常州大学 | 一种n,n-二甲基苄胺及其衍生物的制备方法 |
| CN114989058B (zh) * | 2022-06-02 | 2024-04-16 | 中国科学院成都生物研究所 | 一种手性氯代砜亚胺类化合物及其衍生物的制备方法 |
| JP2025524640A (ja) | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| CN115227712A (zh) * | 2022-07-26 | 2022-10-25 | 上海市第五人民医院 | NaHS在制备治疗骨质疏松药物中的应用 |
| EP4561574A1 (en) | 2022-07-27 | 2025-06-04 | Novartis AG | Dosing regimen for a nlrp3 inhibitor |
| CA3261365A1 (en) | 2022-07-28 | 2024-02-01 | Ac Immune Sa | NEW COMPOUNDS |
| KR20260027946A (ko) | 2023-06-02 | 2026-03-03 | 머크 샤프 앤드 돔 엘엘씨 | Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클 |
| TW202513060A (zh) | 2023-09-29 | 2025-04-01 | 瑞士商諾華公司 | 用於降低心血管疾病的風險之nlrp3抑制劑 |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666506A (en) | 1984-08-08 | 1987-05-19 | E. I. Du Pont De Nemours And Company | Herbicidal pyrimidines |
| TW221049B (https=) * | 1991-12-20 | 1994-02-11 | Lilly Co Eli | |
| US5258406A (en) | 1991-12-20 | 1993-11-02 | Eli Lilly And Company | Sulfonimidamides |
| US5169860A (en) | 1992-03-13 | 1992-12-08 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| AU723895B2 (en) | 1997-01-29 | 2000-09-07 | Pfizer Inc. | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| WO2001019390A1 (en) | 1999-09-14 | 2001-03-22 | Pfizer Products Inc. | Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| CA2369967A1 (en) | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| CN102396192B (zh) | 2009-04-16 | 2018-02-16 | 皇家飞利浦电子股份有限公司 | 自适应缓冲器状态报告 |
| US9701689B2 (en) | 2012-11-30 | 2017-07-11 | Kyowa Hakko Kirin Co., Ltd. | Substituted pyridines and pyridazines as CCR10 receptor inhibitors |
| KR102727059B1 (ko) * | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| EP3854782A1 (en) | 2016-03-30 | 2021-07-28 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| US11597706B2 (en) | 2016-04-18 | 2023-03-07 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| ES2940611T3 (es) * | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| KR20180134395A (ko) | 2016-04-19 | 2018-12-18 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| CA3047336A1 (en) | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| US11465992B2 (en) | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| CN111094242B (zh) | 2017-07-24 | 2024-02-09 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| RS65492B1 (sr) * | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| BR112021003665A2 (pt) | 2018-09-13 | 2021-05-18 | Bayer Aktiengesellschaft | derivados de heterocicleno como agentes de controle de pragas |
| AU2020208644A1 (en) | 2019-01-18 | 2021-08-26 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
-
2018
- 2018-07-23 RS RS20240513A patent/RS65492B1/sr unknown
- 2018-07-23 CN CN202311185119.6A patent/CN117209447A/zh active Pending
- 2018-07-23 DK DK18752376.6T patent/DK3658539T3/da active
- 2018-07-23 LT LTEPPCT/US2018/043338T patent/LT3658539T/lt unknown
- 2018-07-23 EP EP18752376.6A patent/EP3658539B1/en active Active
- 2018-07-23 CA CA3068836A patent/CA3068836A1/en active Pending
- 2018-07-23 PL PL18752376.6T patent/PL3658539T3/pl unknown
- 2018-07-23 PT PT187523766T patent/PT3658539T/pt unknown
- 2018-07-23 BR BR112020001476-1A patent/BR112020001476A2/pt unknown
- 2018-07-23 IL IL271259A patent/IL271259B2/en unknown
- 2018-07-23 CR CR20200037A patent/CR20200037A/es unknown
- 2018-07-23 EP EP24151235.9A patent/EP4349820A3/en active Pending
- 2018-07-23 HR HRP20240521TT patent/HRP20240521T1/hr unknown
- 2018-07-23 CU CU2020000004A patent/CU24615B1/es unknown
- 2018-07-23 SI SI201831090T patent/SI3658539T1/sl unknown
- 2018-07-23 PE PE2020000150A patent/PE20200723A1/es unknown
- 2018-07-23 US US16/632,849 patent/US11203579B2/en active Active
- 2018-07-23 FI FIEP18752376.6T patent/FI3658539T3/fi active
- 2018-07-23 MX MX2020000911A patent/MX2020000911A/es unknown
- 2018-07-23 HU HUE18752376A patent/HUE066566T2/hu unknown
- 2018-07-23 KR KR1020207004803A patent/KR102565167B1/ko active Active
- 2018-07-23 CN CN201880050915.XA patent/CN111094243B/zh active Active
- 2018-07-23 JP JP2020503754A patent/JP7412328B2/ja active Active
- 2018-07-23 ES ES18752376T patent/ES2988798T3/es active Active
- 2018-07-23 CN CN202310765173.1A patent/CN117143042A/zh active Pending
- 2018-07-23 AU AU2018307743A patent/AU2018307743C1/en active Active
- 2018-07-23 NZ NZ761026A patent/NZ761026A/en unknown
- 2018-07-23 SG SG11201912166XA patent/SG11201912166XA/en unknown
- 2018-07-23 WO PCT/US2018/043338 patent/WO2019023147A1/en not_active Ceased
-
2019
- 2019-09-16 US US16/572,528 patent/US10654816B2/en active Active
- 2019-12-09 ZA ZA2019/08154A patent/ZA201908154B/en unknown
-
2020
- 2020-01-17 CO CONC2020/0000527A patent/CO2020000527A2/es unknown
- 2020-01-17 PH PH12020500127A patent/PH12020500127A1/en unknown
- 2020-01-23 SA SA520411125A patent/SA520411125B1/ar unknown
- 2020-01-23 DO DO2020000012A patent/DOP2020000012A/es unknown
- 2020-01-24 CL CL2020000215A patent/CL2020000215A1/es unknown
- 2020-01-24 EC ECSENADI20205581A patent/ECSP20005581A/es unknown
- 2020-01-26 JO JOJO/P/2020/0011A patent/JOP20200011B1/ar active
-
2021
- 2021-10-07 US US17/496,375 patent/US11724992B2/en active Active
-
2023
- 2023-05-18 US US18/319,630 patent/US12084424B2/en active Active
- 2023-12-26 JP JP2023218835A patent/JP7654767B2/ja active Active
-
2025
- 2025-03-18 JP JP2025044149A patent/JP7813931B2/ja active Active